Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Retreatment with peg-inte… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse

Artikel i vetenskaplig tidskrift
Författare Martin Lagging
Karolina Rembeck
M. R. Buhl
P. Christensen
O. Dalgard
M. Farkkila
Kristoffer Hellstrand
N. Langeland
Magnus Lindh
Johan Westin
Gunnar Norkrans
Publicerad i Scandinavian Journal of Gastroenterology
Volym 48
Nummer/häfte 7
Sidor 839-847
ISSN 0036-5521
Publiceringsår 2013
Publicerad vid Institutionen för biomedicin, avdelningen för infektionssjukdomar
Sidor 839-847
Språk en
Länkar dx.doi.org/10.3109/00365521.2013.79...
Ämnesord CXCL10, genotype 2, genotype 3, HCV, IL28B, hepatitis C Virus, interferon, IP-10, relapse, ribavirin, viral response, hcv genotypes, therapy, rna, fibrosis, predicts, peginterferon-alpha-2a, ifn-alpha-2a, association, cirrhosis
Ämneskategorier Virologi

Sammanfattning

Objectives. Uncertainty remains regarding the efficacy of retreatment with current standard-of-care peg-interferon (peg-IFN) and ribavirin among patients infected with hepatitis C virus (HCV) genotypes 2 or 3 with relapse after prior therapy. Materials and methods. Seventy-one patients with chronic HCV genotype 2/3 with prior relapse were enrolled in a phase III multicenter study. Patients were retreated with peg-IFN alpha-2a 180 mu g per week and ribavirin 1000/1200 mg daily. Patients having received previous therapy for 24 weeks were retreated for 48 weeks (Group A), whereas patients having received at least 12 weeks but less than 24 weeks of treatment were allocated to either 48 (Group B) or 24 weeks (Group C) on the basis of whether they had achieved rapid virological response (RVR). Results. Sustained virological response (SVR) rates of 53%, 81% and 75% were achieved in groups A, B and C, respectively. Patients with favorable baseline characteristics, e. g., less advanced liver fibrosis, age < 40 years, duration of infection < 20 years, or BMI < 25 kg/m(2), tended to have more favorable outcomes. All patients achieving HCV RNA below 1000 IU/mL day 6 achieved SVR in contrast to none of the patients with detectable HCV RNA at week 12. Conclusions. Retreatment with peg-IFN and ribavirin for 24-48 weeks entails SVR among the majority of HCV genotype 2/3 infected patients with prior relapse. However, in light of the prolonged treatment duration, moderate effect and considerable side effects, deterring therapy until new options are available may be preferential, particularly in patients previously treated for 24 weeks.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?